Tugba Yildiran Ozmen

Tugba Yildiran Ozmen

Auto-generated profile, based on publicly available information

Tugba Yildiran Ozmen

Knight Cancer Institute 4 Division of Oncological Sciences , Portland, Oregon

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXi Li
Xi Li
APAlfonso Poire
Alfonso Poire
KJKang Jin Jeong
Kang Jin Jeong
DZDong Zhang
Dong Zhang
TOTugba Yildiran Ozmen
Tugba Yildiran Ozmen
GMGordon B. Mills
Gordon B. Mills
Although Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved in multiple diseases, including BRCA1/2 mutant breast cancer, responses are usually transient requiring the deployment of combination therapies for optimal efficacy. Here we thus explore mechanisms underlying sensitivity and resistance to PARPi using two intrinsically PARPi sensitive (T22) and resistant (T127) syngeneic murine breast cancer models in female mice. We demonstrate that tumor associated macrophages (TAM) potentially contribute to the differential sensitivity to PARPi. By single-cell RNA-sequencing, we identify a TAM_C3 cluster, expressing genes implicated in anti-inflammatory activity, that is enriched in PARPi resistant T127 tumors and markedly decreased by PARPi in T22 tumors. Rps19/C5aR1 signaling is selectively elevated in TAM_C3. C5aR1 inhibition or transferring C5aR1hicells increases and decreases PARPi sensitivity, respectively. High C5aR1 levels in human breast cancers are associated with poor responses to immune checkpoint blockade. Thus, targeting C5aR1 may selectively deplete pro-tumoral macrophages and engender sensitivity to PARPi and potentially other therapies.

4 September 2025 in Cancer Letters
Verified
Journal Article
Open access
SPSoon Young Park
Soon Young Park
KJKang Jin Jeong
Kang Jin Jeong
APAlfonso Poire
Alfonso Poire
BJBo Young Jeong
Bo Young Jeong
YSYuhan Sheng
Yuhan Sheng
GMGordon B. Mills
Gordon B. Mills
Gemcitabine, a ribonucleotide reductase (RNR) inhibitor, is active in pancreatic ductal carcinoma (PDAC) patients, but unfortunately has a limited impact on long term outcomes. Gemcitabine induces nucleotide deficiency, DNA damage including single stranded DNA (ssDNA) and replication stress (RS). DNA damage can activate cyclic GMP-AMP synthase (cGAS), leading to genome instability, micronucleus generation, and immune activation. In model systems, gemcitabine resistance can be overcome by combination treatment with the ataxia telangiectasia and Rad3-related inhibitor (ATRi; AZD6738) that blocks S and G2 checkpoints, although underlying mechanisms remain to be fully elucidated. We show that cells with low basal RS are resistant to gemcitabine, which could be overcome by combination treatment with AZD6738 through elevation of RS, phospho-RPA32 exhaustion, and mitotic catastrophe in PDAC cell models. Gemcitabine induces nuclear cGAS accumulation independent of STING-mediated immune activation. The binding of nuclear cGAS to γH2AX at double strand DNA breaks (DSBs) plays a pivotal role in RS activation and mitotic catastrophe in gemcitabine and AZD6738 treated cells.

30 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ZMZahi I. Mitri
Zahi I. Mitri
ACAllison L. Creason
Allison L. Creason
JSJayne Stommel
Jayne Stommel
TOTugba Y. Ozmen
Tugba Y. Ozmen
MRMatthew J. Rames
Matthew J. Rames
SPSmmart Clinical Trials Program
Smmart Clinical Trials Program
In syngeneic murine breast cancer models, poly(ADP-ribose) polymerase inhibitor (PARPi) and anti-PD-L1 combinations induce deep, sustained responses independent of BRCA1 or BRCA2 mutation (BRCAm) status. We therefore investigated this combination in the AMTEC clinical trial, in which a one-month olaparib run-in was followed by combined olaparib and durvalumab in participants with non-BRCAm metastatic triple negative breast cancer. To characterize adaptive responses to olaparib monotherapy, paired biopsies taken before and during the PARPi lead-in were deeply characterized by DNA, RNA, and protein multi-omic analyses, including spatially resolved single-cell proteomics for tumor and immune contexture. We identified multiple potential tumor-intrinsic and microenvironmental biomarkers from pre-treatment and on-olaparib biopsies that robustly predicted participant response to combined olaparib and durvalumab. Notably, the on-olaparib biopsy provided the greatest information content, suggesting that early adaptations of malignant and immune cells to PARPi can serve as a predictor of potential benefit from combined PARPi and anti-PD-L1 therapy.

26 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FOFurkan Ozmen
Furkan Ozmen
TOTugba Y. Ozmen
Tugba Y. Ozmen
AOAysegul Ors
Aysegul Ors
MJMahnaz Janghorban
Mahnaz Janghorban
MRMatthew J. Rames
Matthew J. Rames
HMHisham Mohammed
Hisham Mohammed
Metastatic breast cancer remains largely incurable, and the mechanisms underlying the transition from primary to metastatic breast cancer remain elusive. We analyzed the complex landscape of primary and metastatic breast cancer using scRNA-seq data from twenty-three female patients with either primary or metastatic disease to elucidate the genetic and molecular mechanisms underlying changes in the metastatic tumor ecosystem. We identify specific subtypes of stromal and immune cells critical to forming a pro-tumor microenvironment in metastatic lesions, including CCL2+ macrophages, cytotoxic T cells with an exhausted gene signature, and FOXP3+ regulatory T cells. Analysis of cell-cell communication highlights a marked decrease in tumor-immune cell interactions in metastatic tissues, likely strengthening the immunosuppressive microenvironment. In contrast, primary breast cancer samples displayed increased activation of the TNF-α signaling pathway via NF-kB, indicating a potential therapeutic target. Our study comprehensively characterizes the transcriptional landscape encompassing primary and metastatic breast cancer.

23 October 2025 in Cancer Research
Verified
Journal Article
Closed access
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine T. Huang
Elaine T. Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens
Dedifferentiation programs are commonly enacted during breast cancer progression to enhance tumor cell fitness. Increased cellular plasticity within the neoplastic compartment of tumors correlates with disease aggressiveness, often culminating in greater resistance to cytotoxic therapies or augmented metastatic potential. In this study, we found that subpopulations of dedifferentiated neoplastic breast epithelial cells express canonical leukocyte cell surface receptor proteins and have thus named this cellular program “immune mimicry.” Analysis of public human breast tumor single-cell RNA sequencing datasets and histopathologic breast tumor specimens, as well as functional experiments in vitro in breast cancer cell lines and in vivo in murine transgenic and cell line–derived mammary cancer models, showed that neoplastic cells engaged in immune mimicry. Immune-mimicked neoplastic cells harbored hallmarks of dedifferentiation and were enriched in treatment-resistant and high-grade breast tumors. In aggressive breast cancer cell lines, antiproliferative cytotoxic chemotherapies drove epithelial cells toward immune mimicry. The expression of the CD69 leukocyte activation protein by neoplastic cells conferred a proliferative advantage that facilitated early tumor growth. Together, these findings suggest that neoplastic breast epithelial cells upregulating leukocyte surface receptors potentiate malignancy and that neoplastic immune mimicry has potential clinical utility for patient prognosis and stratification. Significance: A subset of neoplastic breast epithelial cells express surface receptors canonically attributed to leukocytes and are associated with therapy resistance and aggressive tumor behavior.

2 February 2026
Verified
Other
Open access
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine T. Huang
Elaine T. Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens